For years, the United States and the United Kingdom have stood on opposite ends of the drug pricing spectrum. The US has historically allowed manufacturers to set list prices with relatively few constraints, while the UK’s NHS relies on strict cost effectiveness evaluations through NICE.... Continue reading
Return to previous page